Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienn
• The total investment is around a half billion euro.
• With this investment, Boehringer Ingelheim plans on adding more than 400 jobs.
• The biopharmaceutical production plant will go into operation by 2021.
INGELHEIM, Germany ...
0评论2015-12-231432
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienn
• The total investment is around a half billion euro.
• With this investment, Boehringer Ingelheim plans on adding more than 400 jobs.
• The biopharmaceutical production plant will go into operation by 2021.
INGELHEIM, Germany ...
0评论2015-12-232099
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienn
• The total investment is around a half billion euro.
• With this investment, Boehringer Ingelheim plans on adding more than 400 jobs.
• The biopharmaceutical production plant will go into operation by 2021.
INGELHEIM, Germany ...
0评论2015-12-232013
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienn
• The total investment is around a half billion euro.
• With this investment, Boehringer Ingelheim plans on adding more than 400 jobs.
• The biopharmaceutical production plant will go into operation by 2021.
INGELHEIM, Germany ...
0评论2015-12-231846
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelum
Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in ...
0评论2015-12-232036
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelum
Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in ...
0评论2015-12-232021
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelum
Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in ...
0评论2015-12-231345
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelum
Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in ...
0评论2015-12-231693
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelum
Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in ...
0评论2015-12-231893
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelum
Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in ...
0评论2015-12-232001
Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelum
Initiation of Phase III JAVELIN Ovarian 200 trial investigating avelumab as a treatment for platinum-resistant/refractory ovarian cancer
Initiation of Phase III JAVELIN Bladder 100 trial investigating avelumab as a maintenance treatment, in ...
0评论2015-12-231578
中興通訊為中國使用者推出6英寸AXON MAX手機及Global VIP Passport服務
北京--(美國商業資訊)--中興通訊終端事業部(ZTE Mobile Devices)今天宣佈，推出高性能AXON旗艦系列的最新終極版智慧型手機AXON MAX。與此同時，該公司還宣佈推出“Global VIP Passport”特殊服務，以迎合其AXON手機用戶的需求。自上市以來，AXON系列在使用者洞察的帶動下不斷發展，中興通訊此時即根據其對使用者洞察的持續關注而提供這項高階售後服務，意在與其高階手機系列相互輝映。
這份智慧新聞稿包含多媒體內...
0评论2015-12-221364
富瑞集团公布2015年第四财季业绩
纽约--(美国商业资讯)--富瑞集团(Jefferies Group LLC)今日公布了其2015年第四财季的业绩。
以下为截至2015年11月30日的3个月的业绩摘要，调整后的数值不包含Bache业务的运营业绩和债权处理及清算成本，
投资银行业务净营收为3.73亿美元
销售和交易净营收合计1.32亿美元
调整后净营收总额5.13亿美元（不包括Bache业务）
...
0评论2015-12-221398
NTT DATA收购台湾应用管理顾问股份有限公司---意欲增强全球SAP应对能力
东京 & 北京--(美国商业资讯)--近日，NTT DATA Corporation（董事长：岩本敏男， 总部：东京江东区，以下简称NTT DATA）收购了台湾的SAP合作伙伴台湾应用管理顾问股份有限公司（英文名：Taiwan Application Service Management Consulting Co., Ltd.，Managing Director：Hsieh Chen Kuo，总部：台湾·台北市，以下简称TASMC公司）100%的股权，至此TASMC公...
0评论2015-12-221744
中興通訊美國和休士頓火箭隊完成第三個年度分享季活動
中興通訊和火箭隊透過三項當地活動，讓休士頓地區數百人受益
休士頓--(美國商業資訊)--美國第四大智慧型手機供應商和非合約機市場第二大供應商*中興通訊美國(ZTE USA)和休士頓火箭隊第三次攜手合作，在休士頓地區舉辦三項活動，為第三個年度分享季(Season of Giving)畫下圓滿句點。過去兩個月，中興通訊員工和火箭隊成員、球員和工作人員舉行了多項慈善活動，在今年的節日季協助那些有需要的人。
這份智慧新聞稿包含多媒體內容。完整新聞稿可在以下網址查閱：http://...
0评论2015-12-221325
Binatone Global任命新的主管團隊，強化其IoT聯網解決方案的業界地位
在收購Motorola Mobility配件業務後，Binatone宣佈由David Westendorf擔任總裁，負責帶領世界級的領導團隊
洛杉磯--(美國商業資訊)--繼10月份購買Motorola Mobility配件產品的許可後，消費電子巨人Binatone Global今天宣佈任命4位高階主管，以將其Hubble IoT Connectivity Platform引進主流市場。這次的任命是Binatone轉型策略的一部分，即透過物聯網(IoT)聯網產品提升消費者的情感體驗。
&n...
0评论2015-12-212208
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694* to become a new treatment option for EGFR mutation-positive lung cancer
In 62% of patients with T790M-positive NSCLC objectiv...
0评论2015-12-211970
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694* to become a new treatment option for EGFR mutation-positive lung cancer
In 62% of patients with T790M-positive NSCLC objectiv...
0评论2015-12-211324
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694* to become a new treatment option for EGFR mutation-positive lung cancer
In 62% of patients with T790M-positive NSCLC objectiv...
0评论2015-12-211673
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694* to become a new treatment option for EGFR mutation-positive lung cancer
In 62% of patients with T790M-positive NSCLC objectiv...
0评论2015-12-211375